Bank of Suzhou

Bank of Suzhou released its first-half 2026 report, with total operating revenue of 7.354 billion yuan, up 13.08% year on year, and net profit attributable to the parent company of 3.401 billion yuan, up 8.51% year on year, both rising for five consecutive years. Net cash inflow from operating activities was 37.914 billion yuan, up 133.09% year on year. The company's asset-liability ratio was 92.42%, return on equity was 5.32%, and diluted earnings per share was 0.71 yuan, up 7.58% year on year. The number of shareholders was 56,800, and the top ten shareholders held 42.62% of total share capital.

China's A-share market saw all three major indices decline in the morning session on July 13, with the Shenzhen Component Index and the STAR Composite Index both falling more than 2%. Over 4,500 stocks across the market ended in the red. The memory chip sector suffered a sharp pullback, with Demingli hitting its daily limit down, Shannon Core Innovation plunging 19.93%, and Puya Semiconductor and Beijing Junzheng both dropping over 11%. Bank stocks bucked the trend and moved higher, with Bank of Suzhou surging over 6%, Bank of Ningbo rising over 4%, and Industrial and Commercial Bank of China and Bank of Communications gaining more than 2%. The total dividends of 41 banks for the 2025 fiscal year exceeded 645.6 billion yuan, setting a new record. The traditional Chinese medicine sector saw a short-term spike, with Longshen Rongfa hitting its 20% daily limit up and Tianmu Pharmaceutical reaching its 10% daily limit up. The State Council recently approved the 15th Five-Year Plan for the Revitalization and Development of Traditional Chinese Medicine.